GDF15 Activates Brain-to-Liver Glucocorticoid Pathway to Cut MASH Inflammation Independent of Weight Loss

The team combined genetic knockouts, pharmacological GDF15 administration, spatial transcriptomics, and genomic profiling in diet-induced MASH mice that recapitulate human disease progression. They traced GDF15 action to brainstem neurons that trigger adrenal glucocorticoid release, which then reprograms hepatic immune cells toward an anti-inflammatory state and slows collagen deposition. This pathway operated even when caloric intake and body mass remained unchanged, separating the anti-fibrotic signal from the hormone’s established appetite-suppressing effects.

The finding builds on the same group’s 2023 Cell Metabolism paper showing GDF15 preserves energy expenditure during weight loss. Together the studies indicate GDF15 has at least two distinct therapeutic windows: one metabolic and one anti-inflammatory. Because current GLP-1 receptor agonists primarily act through weight reduction yet leave residual inflammation in many MASH patients, a GDF15-based adjunct could address the unmet need for direct anti-fibrotic action.

Key limitation is reliance on rodent models whose glucocorticoid dynamics differ from humans; human translation will require safety data on sustained glucocorticoid signaling and fibrosis endpoints. A Phase 1b trial of a long-acting GDF15 analog in biopsy-confirmed MASH is already planned at McMaster for late 2026.

If the neural-glucocorticoid axis is confirmed in larger mammals, GDF15 mimetics could enter combination regimens with GLP-1 drugs within 24 months, targeting the roughly 25 % of MASH patients who progress despite weight loss.